Evotec SE (EVO) Current Deferred Revenue (2009 - 2026)
Evotec SE's (EVO) quarterly Current Deferred Revenue came in at $79.5 million in Q2 2026, down 47.02% year-over-year from $150.1 million in Q2 2025, and down 39.21% quarter-over-quarter from $130.8 million in Q1 2026.
Analysis
Evotec SE (EVO) Current Deferred Revenue (2009 - 2026) Analysis & Trends
Evotec SE has disclosed Current Deferred Revenue across 10 years of filings, most recently posting $79.5 million for Q2 2026.
- In Q2 2026, Current Deferred Revenue fell 47.02% year-over-year to $79.5 million; the TTM figure through Jun 2026 stood at $79.5 million (down 47.02% YoY), while the FY2025 annual figure was $118.5 million, up 2.67% from the prior year.
- Current Deferred Revenue came in at $79.5 million for Q2 2026 at Evotec SE, down from $130.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $151.2 million in Q2 2023 to a low of -$143.0 million in Q2 2022.
- Average Current Deferred Revenue over 5 years is $104.3 million, with a median of $125.1 million recorded in 2022.
- Year-over-year, Current Deferred Revenue soared 205.8% in 2023 and plunged 47.02% in 2026.
- Over 5 years, Current Deferred Revenue stood at $125.4 million in 2022, then dropped by 16.28% to $105.0 million in 2023, then increased by 8.49% to $113.9 million in 2024, then climbed by 7.14% to $122.0 million in 2025, then slumped by 34.84% to $79.5 million in 2026.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $79.5 million in Q2 2026, $130.8 million in Q1 2026, and $122.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 42.77 Bn | 40.69 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn |
| 3 | Charles River Laboratories International | 13.37 Bn | 13.18 Bn | 452.07 Mn |
| 4 | Icon | 12.49 Bn | 11.56 Bn | 479.29 Mn |
| 5 | Fortrea Holdings | 1.58 Bn | 1.42 Bn | 139.20 Mn |
| 6 | Evotec SE | 642.83 Mn | 216.96 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 422.55 Mn | 338.02 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.16 Mn | 69.16 Mn | 7.03 Mn |
| 9 | MindWalk Holdings | 59.83 Mn | 51.55 Mn | 1.82 Mn |
| 10 | VivoSim Labs | 1.45 Mn | 1.45 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79.52 Mn |
| Mar 31, 2026 | 130.81 Mn |
| Dec 31, 2025 | 122.05 Mn |
| Sep 30, 2025 | 124.89 Mn |
| Jun 30, 2025 | 150.09 Mn |
| Mar 31, 2025 | 132.29 Mn |
| Dec 31, 2024 | 113.91 Mn |
| Sep 30, 2024 | 108.38 Mn |
| Dec 31, 2023 | 105.00 Mn |
| Jun 30, 2023 | 151.24 Mn |
| Dec 31, 2022 | 125.41 Mn |
| Sep 30, 2022 | 133.49 Mn |
| Jun 30, 2022 | -142.95 Mn |
| Mar 31, 2022 | 126.67 Mn |
| Dec 31, 2021 | 128.19 Mn |
| Sep 30, 2021 | 71.60 Mn |
| Dec 31, 2020 | -17.43 Mn |
| Dec 31, 2019 | -16.25 Mn |
| Sep 30, 2010 | 6.23 Mn |
| Jun 30, 2010 | 6.32 Mn |